Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CNS PHARMACEUTICALS INC
CNSP | US
3.00
USD-0.08
-2.60%
CNSP | US
About CNS PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
05/03/2026
Close
3.00
Open
3.02
High
3.03
Low
2.87
CNS Pharmaceuticals Inc. a clinical pharmaceutical company engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals Inc. Reata Pharmaceuticals Inc. Pomeranian Medical University and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston Texas.
View LessCNSP | US
Risk
64.1
Sharpe
-0.84
Luna's Score
37/100
Recommendation
Sell
Luna says (CNSP | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
37.7%1 month
64.1%3 months
81.6%6 months
80.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.57
Debt to equity
-0.03
Debt to assets
0.05
Ent. to EBITDA
0.40
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-15.98M
MarketCap
96.44M
MarketCap(USD)
96.44M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.02K
Short ratio
0.44
Short perc.
2.11
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.47
Range1M
2.74
Range3M
6.05
Volumes: Market Activity
Rel. volume
0.56
Price X volume
33.78K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.40 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.57 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 81.61 | 72.80 | Par |
| Debt to Equity | -0.03 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 96.44M | 3.66B | Emerging |
